XDx Inc., a South San Francisco-based molecular diagnostics company that develops tests for the monitoring of transplant rejection and autoimmune diseases, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol XDXI, with JPMorgan and Morgan Stanley serving as co-lead underwriters.
The company has raised over $46 million in VC funding, from firms like Kleiner Perkins Caufield & Byers (17% pre-IPO stake), TPG Ventures (17%), Sprout Group (11.7%), Burrill & Co. (9.5%), DAG Ventures (7.2%), Integral Capital Partners (5.8%) and Intel Capital. www.xdx.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.